click below
click below
Normal Size Small Size show me how
ADHD & stimulants
Uni of Notts, Neurobiology of disease, second year, topic 2
| Term | Definition |
|---|---|
| ADHD main diagnostic criteria (2) | Inattention: difficulty & avoidance sustaining attention, distracted, disorganised, bad listener & forgetful Hyperactivity: Fidgeting, restlessness, excessive talking & volume, poor social filter & intrudes on social settings |
| Clinical diagnostic requirements: Children | >6 symptoms of any category before age 12. Need to be present in at least 2 settings of: School, Home, or social life. Symptoms must be developmentally inappropriate for age groups |
| Clinical diagnostic requirements: Adolescents & adults | >/=5 symptoms from either category. Diagnoses are more difficult & adults are usually just diagnosed as combined type (inattentive & hyperactive) |
| Possible link between ADHD & criminals | 20% of inmates are diagnosed. ADHD patients deeply rooted in present, impaired future prediction causing disconnect between actions & consequences |
| Genetic:environmental cause ratio | 4:1 genetic:environmental. 80% of the condition is heritable in twins |
| Environmental factors (neonatal & postnatal) | Neonatal hypoxia, maternal toxins (tobacco, alcohol, lead etc.) & premature birth Encephalitis, seizure disorder, & acquired brain trauma |
| Neuroanatomical differences are in ADHD | Smaller right frontal lobe, smaller basal ganglia (normalising by ~18), & smaller cerebellum. Reduced striatal metabolism & hyperactive sensory cortex |
| Volumetric differences & correlation to severity | Reductions correlate with symptom severity & appear early in life. Implicated brain regions have smaller volumes & poorer synaptic connectivity |
| Key brain regions implicated in ADHD | Dorsolateral prefrontal cortex, caudate, & putamen (fronto‑striatal circuits) |
| Role of DAT in ADHD neurobiology | Higher DAT density in the striatum reduces synaptic dopamine from radiolabelled proteins showing higher frequency than control group |
| DRD4 7‑repeat allele & its importance | 48‑bp Variable Number Tandem Repeat variant of a D4 receptor associated with ADHD, linked to inattention, novelty seeking & reduced AC coupling. 1.9:1 pooled odds ratio |
| DAT1 480‑bp repeat variant | High‑risk allele of gene 5015.2 associated with elevated DAT expression and reduced dopamine signalling in the striatum. 1.16:1 pooled odds ratio |
| Effects of methylphenidate on DAT expression | 4 weeks of treatment significantly reduces DAT ligand binding however, after 12 months neuroplasticity upregulates DAT until it can combat the drug |
| Therapeutic benefits of psychostimulants on ADHD | They restore dopamine signalling in fronto‑striatal circuits, improving attention, working memory, & behavioural inhibition; & inhibit glutamate signalling |
| Glutamatergic signalling in ADHD | Many NMDA receptors in fronto-striatal & reward pathways are implicated with ADHD behaviours by causing under or overexcitability & further dysregulating dopamine |
| Mechanism of non‑stimulant ADHD medications | Inhibiting NET increases NE in the prefrontal cortex. Less addictive but less effective |
| Newer ADHD treatments | Combining α‑adrenoceptor agonists (e.g., guanfacine, clonidine) & tricyclic antidepressants or antagonising NMDA receptors |
| Prevalence & comorbidities of ADHD | Affects 3–5% of the population; more likely to be diagnosed with hyperkinetic disorder, epilepsy, anxiety, depression, opposition defiance disorder, tics, conduct disorders, mood disorders. 31% chance of appearing on its own |
| Gender differences with ADHD | Males 2-3x more likely to be diagnosed & show more hyperactivity & conduct disorders; females show weaker emotional regulation & self-esteem. Both usually have exceptional creativity & intelligence but suffer academically |